Scott Alexander examines the complexities of abolishing the FDA and proposes more practical alternatives to increase medical innovation while maintaining safeguards. Longer summary

Scott Alexander discusses the challenges of abolishing the FDA, a popular libertarian idea. He explores various issues that would arise, such as the fate of prescription medications, drug contamination inspections, and the potential for exploitation by unethical companies. The post then proposes two more practical alternatives to complete FDA abolition: legalizing artificial supplements and creating an 'experimental drug' category. These suggestions aim to increase medical innovation and access while maintaining some safeguards. Shorter summary

Scott Alexander summarizes and responds to various comments on his kidney donation post, covering a wide range of related topics and perspectives. Longer summary

Scott Alexander provides highlights from comments on his kidney donation post, covering various perspectives and topics. These include comments from other kidney donors and recipients, discussions on opt-out organ donation systems, debates on radiation risk from screening tests, issues with rejection during the donation process, polls about willingness to donate, and developments in artificial organ technology. Scott also responds to many comments, offering additional insights and reflections on the donation process and related ethical considerations. Shorter summary

Scott Alexander recounts his experience donating a kidney, from initial motivation to post-surgery recovery, while discussing the broader context of organ donation. Longer summary

Scott Alexander describes his journey to donate a kidney, including his motivations, the medical process, and the challenges he faced. He discusses the effectiveness of kidney donation compared to other forms of altruism, the stigma around mental health in the donation process, and the need for systemic changes to address the kidney shortage. Scott also reflects on the experience of the surgery and recovery, and encourages others to consider donation. Shorter summary

Scott Alexander responds to comments on his post about new telemedicine regulations, addressing various concerns and criticisms raised by readers. Longer summary

Scott Alexander summarizes and responds to various comments on his original post about new telemedicine regulations. He addresses concerns about drug addiction, debates the effectiveness of telemedicine compared to in-person care, discusses the issue of 'pill mills', clarifies his analogy about blind people accessing Braille, responds to criticism of his characterization of Christian doctors, examines which part of the government is responsible for the regulations, and looks at how other countries handle telemedicine prescriptions. Shorter summary

Scott Alexander criticizes new DEA regulations that restrict telemedicine prescriptions for controlled substances, arguing they will harm patients and legitimate practices while failing to prevent abuse. Longer summary

Scott Alexander criticizes new DEA regulations that make it harder for telemedicine doctors to prescribe controlled substances. As a telepsychiatrist, he explains how these rules will negatively impact his practice and patients, especially those who rely on controlled substances for conditions like ADHD or anxiety. He argues that the new regulations, while intended to prevent overprescribing, will mainly create inconvenience for legitimate practitioners and patients while doing little to stop actual abusers. Scott outlines the loopholes in the law and how they highlight its absurdity, predicting that these rules will make telemedicine less accessible and effective in the long run. Shorter summary

Scott Alexander compiles reader comments on healthcare systems in various countries, discussing economics, drug pricing, and personal experiences. Longer summary

This post is a collection of reader comments on healthcare systems in various countries, focusing on the US, Germany, Netherlands, UK, Australia, Switzerland, and several others. It covers topics like drug pricing, healthcare economics, and personal experiences with different systems. The post is structured into four main sections: comments on US healthcare, discussions on drug pricing and subsidies, explanations of why healthcare economics are unique, and detailed accounts of healthcare systems in specific countries. Shorter summary

Scott Alexander defends his criticism of the FDA's approval process in the infant fish oil case, arguing that systemic issues cause harmful delays even when the FDA follows its mandate. Longer summary

Scott Alexander responds to Kevin Drum's criticism of his interpretation of the infant fish oil story. He maintains that his account was substantially correct, despite some minor errors. Scott argues that the FDA's approval process, while following its mandate, causes unnecessary delays in life-saving treatments. He uses analogies to illustrate how the FDA's structure can be problematic even when individual employees perform well. Scott emphasizes that his criticism is not about the FDA failing its mandate, but about the design of the system itself causing delays in implementing known beneficial treatments. He concludes by addressing Drum's skepticism of FDA critics, arguing that anger towards the FDA often comes from personal experiences with its shortcomings. Shorter summary

Scott Alexander presents numerous examples of how the U.S. employer-provided health insurance system fails even insured, well-off individuals, arguing that almost any alternative system would be better. Longer summary

Scott Alexander critiques the employer-provided health insurance system in the United States, presenting numerous real-life examples of how it fails even well-off, insured individuals. He argues that the system creates unnecessary barriers to care, disrupts continuity of treatment, and traps people in undesirable life situations. The post illustrates how the current system fails not just the poor and uninsured, but also those who seemingly should benefit from it. Scott concludes that virtually any other healthcare system would resolve these issues. Shorter summary

Scott Alexander offers various strategies for obtaining affordable mental health care and medication in the US, including discount programs, therapy alternatives, and supplement options. Longer summary

This post provides detailed advice on how to access mental health care and medication on a budget in the US. Scott outlines various strategies for obtaining prescription medications at lower costs, including using discount websites, pill splitting, and patient assistance programs. He also discusses affordable therapy options and supplement alternatives to prescription drugs. The post is aimed at those who don't qualify for government assistance and includes both legal and potentially legal methods. Scott emphasizes that this is not medical advice and should be used at one's own risk. Shorter summary

Scott Alexander discusses potential Trump administration health-related appointments, focusing on FDA commissioner candidates Jim O'Neill and Balaji Srinivasan, and their potential to implement beneficial reforms. Longer summary

Scott Alexander discusses potential Trump administration picks for key health-related positions, particularly the FDA commissioner and NIH chief. He expresses excitement about the possibility of Jim O'Neill or Balaji Srinivasan being chosen for FDA commissioner, viewing them as principled libertarians who could implement beneficial reforms. Alexander outlines several policies these candidates might pursue, such as medical reciprocity with other countries and streamlining generic drug approvals. He also mentions John Ioannidis as a surprising potential pick for NIH chief, praising his work in improving medical research standards. The post concludes by noting that pharmaceutical industry stocks haven't moved much in response to these potential appointments. Shorter summary

Scott argues against Vox's proposal for drug price controls, citing studies that such policies would significantly reduce pharmaceutical innovation and potentially cost millions of life-years long-term. Longer summary

Scott Alexander responds to Sarah Kliff's Vox article about drug pricing, arguing that her proposal for price controls on brand-name drugs would significantly decrease pharmaceutical innovation. He cites multiple economic studies suggesting price controls reduce R&D and new drug development. Scott argues that while price controls might lower costs in the short-term, they could cost millions of life-years long-term by reducing new drug creation. He suggests focusing on increasing generic drug competition and reducing unnecessary prescriptions of expensive brand-name drugs with cheap generic alternatives as better solutions to high drug prices. Shorter summary

Scott Alexander criticizes the idea that prisons have replaced mental hospitals, arguing for better community and forensic mental health care instead of long-term institutionalization. Longer summary

Scott Alexander critiques a Vox article that suggests America's criminal justice system has become a substitute for the gutted mental health system. He argues that this view is misguided, explaining that mental health spending hasn't decreased but shifted from long-term state hospitals to community care. Scott contends that the high number of mentally ill people in prison is due to shared risk factors with criminality, not a lack of mental health care. He emphasizes that most mentally ill people can live outside institutions and shouldn't be institutionalized preemptively. Scott advocates for better funding of community and forensic mental health systems rather than reopening state-run long-term mental hospitals, which he views as problematic. Shorter summary